A Phase 2 interventional study of Carboplatin/Paclitaxel and Trastuzumab in Endometrial Cancer, sponsored by Yale University. Completed at 20 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2023-05-17.
Sponsored by Yale University · Phase 2, Interventional, and Treatment
How we know · 5 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 715 studies in Endometrial Neoplasms with a site in United States — 195 open to participants now, 284 under way, 22 of them phase 3. Endometrial Neoplasms · United States.
Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 289th largest by enrollment of the 591 interventional ones that give a count, is one of 14 that started in 2011, is one of 178 in phase 2, and was the 176th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →195 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, China and 2 more countries
Ages 18+ · Women only
University of Oklahoma · Sites in United States
Ages 18+ · Women only
Crescent Biopharma, Inc. · Sites in United States
Ages 18+
Sutro Biopharma, Inc. · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
715 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 277 · Phase 2 264 · Phase 3 40 · Phase 4 3
First in 1987; this study’s year is marked. 14 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 60 across the 591 interventional studies, 148 across the 100 observational. Of the 386 that completed or were terminated, 132 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
275 of 715 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,773 studies on the registry; 298 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 5 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
95 of the studies in Endometrial Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03785288Phase 3Kara Romano, MDVaginal Cuff Brachytherapy Fractionation Study | 2027-01-30 |
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT05256225Phase 3National Cancer Institute (NCI)Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | 2027-10-31 |
| NCT02285192Memorial Sloan Kettering Cancer CenterPositron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer | 2026-11 |
Add all 95 to your calendar (.ics) → With an account.
Among the 715 studies in Endometrial Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine Serous Papillary Carcinoma (USPC) patients overexpressing Her2/neu at 3+ level by immunohistochemistry (IHC)or positive by fluorescence in situ hybridization (FISH).
The purpose of this study is to perform a randomized Phase II evaluation of Carboplatin/Paclitaxel with or without Trastuzumab (Herceptin) in patients with HER2/neu+ advanced stage/recurrent disease with an emphasis on determining the progression free survival in USPC patients and assessing immunologic markers predictive of trastuzumab response.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chemotherapy
Drug: Carboplatin/Paclitaxel
Monoclonal antibody
Drug: Trastuzumab
Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
Also known as: Taxus brevifolia, cis-Diammine
Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
Also known as: Herceptin
Progression Free Survival Differences Between Treatment Arms.
Progression free survival differences between treatment arms.
Time frame: 6 years
To Assess the Safety Profile of Trastuzumab in USPC Patients by CTCAE v4.0
To assess the safety profile of trastuzumab in USPC patients by CTCAE v4.0. Presented are counts of those that experience any Serious Adverse Events or All Other Adverse Events.
Time frame: 6 years
To Assess Objective Response Rate (ORR)
To assess objective response rate (ORR)
Time frame: 6 years
To Assess Overall Survival (OS)
To assess overall survival (OS), presented are the number of participants that survived through the duration of the study period.
Time frame: 6 years
| Milestone | Carboplatin/Paclitaxel | Trastuzumab |
|---|---|---|
| Started | 29 | 32 |
| Participants receive drug | 28 | 32 |
| Participants evaluable for pfs | 28 | 30 |
| Completed | 28 | 30 |
| Not completed | 1 | 2 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Physician decision | 0 | 2 |
Progression free survival differences between treatment arms.
| months | Carboplatin/Paclitaxel | Trastuzumab |
|---|---|---|
| Progression Free Survival Differences Between Treatment Arms. | 8.049 (7.129 to 9.692) | 12.945 (10.448 to 18.103) |
To assess the safety profile of trastuzumab in USPC patients by CTCAE v4.0. Presented are counts of those that experience any Serious Adverse Events or All Other Adverse Events.
| Participants | Carboplatin/Paclitaxel | Trastuzumab |
|---|---|---|
| Serious Adverse Events | 6 | 14 |
| All Other Adverse Events | 28 | 32 |
To assess objective response rate (ORR)
| Participants | Carboplatin/Paclitaxel | Trastuzumab |
|---|---|---|
| Complete Response (CR) | 2 | 1 |
| Partial Response (PR) | 4 | 3 |
| Stable Disease (SD) | 1 | 5 |
| Progressive Disease (PD) | 1 | 0 |
To assess overall survival (OS), presented are the number of participants that survived through the duration of the study period.
| Participants | Carboplatin/Paclitaxel | Trastuzumab |
|---|---|---|
| To Assess Overall Survival (OS) | 7 | 9 |
Collected over 30 days post treatment (treatment could last as long as 6 years). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carboplatin/Paclitaxel | 21/28 (75%) | 6/28 (21.4%) | 28/28 (100%) |
| Trastuzumab | 21/32 (65.6%) | 14/32 (43.8%) | 32/32 (100%) |
| Event | Carboplatin/Paclitaxel | Trastuzumab |
|---|---|---|
| Allergic reactionImmune system disorders | 0/28 | 2/32 |
| Abdominal painGastrointestinal disorders | 0/28 | 2/32 |
| Small intestinal obstructionGastrointestinal disorders | 1/28 | 2/32 |
| Blood and lymphatic system disorders - OtherBlood and lymphatic system disorders | 1/28 | 0/32 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/28 | 0/32 |
| HyperglycemiaMetabolism and nutrition disorders | 1/28 | 1/32 |
| Renal and urinary disorders - OtherRenal and urinary disorders | 1/28 | 0/32 |
| Reproductive system and breast disorders - OtherReproductive system and breast disorders | 1/28 | 0/32 |
| Thromboembolic eventVascular disorders | 1/28 | 1/32 |
| GastroparesisGastrointestinal disorders | 1/28 | 0/32 |
| Event | Carboplatin/Paclitaxel | Trastuzumab |
|---|---|---|
| FatigueGeneral disorders | 17/28 | 23/32 |
| NauseaGastrointestinal disorders | 11/28 | 18/32 |
| Peripheral sensory neuropathyNervous system disorders | 15/28 | 17/32 |
| ConstipationGastrointestinal disorders | 9/28 | 17/32 |
| AnemiaBlood and lymphatic system disorders | 13/28 | 16/32 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/28 | 15/32 |
| Abdominal painGastrointestinal disorders | 3/28 | 16/32 |
| DiarrheaGastrointestinal disorders | 5/28 | 13/32 |
| Neutrophil count decreasedInvestigations | 9/28 | 11/32 |
| HypertensionVascular disorders | 5/28 | 11/32 |
Only those evaluable for PFS are included. Three were excluded due to: withdrawal of consent (n = 1) or failure to confirm HER2 positivity by fluorescence in situ hybridization (FISH) after 2+ immunohistochemistry (n = 2).
| Age, Continuous(years) | Carboplatin/Paclitaxel | Trastuzumab | Total |
|---|---|---|---|
| Median | 73 (45 to 88) | 67 (57 to 85) | 69 (45 to 88) |
| Sex: Female, Male(Participants) | Carboplatin/Paclitaxel | Trastuzumab | Total |
|---|---|---|---|
| Female | 28 | 30 | 58 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Carboplatin/Paclitaxel | Trastuzumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 26 | 26 | 52 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Carboplatin/Paclitaxel | Trastuzumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 8 | 10 | 18 |
| White | 17 | 20 | 37 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Region of Enrollment(participants) | Carboplatin/Paclitaxel | Trastuzumab | Total |
|---|---|---|---|
| United States | 28 | 30 | 58 |
| Disease Status(Participants) | Carboplatin/Paclitaxel | Trastuzumab | Total |
|---|---|---|---|
| Advanced | 20 | 21 | 41 |
| Recurrent | 8 | 9 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jun 2011, a primary completion of Jun 2022 and a completion of Jun 2022. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2023, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab